Top Updates Back
Otsuka America Pharmaceutical, Inc
United States of America
Products
Professional Communities
Patient Resources
Family Resources
Medical Information
Brand Portal
508 Carnegie Center Dr, Princeton, NJ 08540, United States
Company name
Group Parent Subsidiary Customer Supplier Alliance Bank Shareholder
Otsuka Pharmaceutical Co., Ltd.
Group company Parent Subsidiary Customer Supplier Alliance Bank, lending and credit Investment, equity and shareholders
Group Parent
Otsuka America, Inc.
Group company Parent Subsidiary Customer Supplier Alliance Bank, lending and credit Investment, equity and shareholders
Group Parent
Otsuka Pharmaceutical Development & Commercialization, Inc.
Group company Parent Subsidiary Customer Supplier Alliance Bank, lending and credit Investment, equity and shareholders
Group Subsidiary
Avanir
Group company Parent Subsidiary Customer Supplier Alliance Bank, lending and credit Investment, equity and shareholders
Group Subsidiary
Akebia Therapeutics
Group company Parent Subsidiary Customer Supplier Alliance Bank, lending and credit Investment, equity and shareholders
Alliance
Novartis
Group company Parent Subsidiary Customer Supplier Alliance Bank, lending and credit Investment, equity and shareholders
Alliance
Pfizer
Group company Parent Subsidiary Customer Supplier Alliance Bank, lending and credit Investment, equity and shareholders
Alliance
Sanofi
Group company Parent Subsidiary Customer Supplier Alliance Bank, lending and credit Investment, equity and shareholders
Alliance
Verily
Group company Parent Subsidiary Customer Supplier Alliance Bank, lending and credit Investment, equity and shareholders
Alliance

9 entries
DateDescription
2002 FDA approves ABILIFY (aripiprazole)
2009 FDA approves SAMSCA (tolvaptan)
2013 FDA approves ABILIFY MAINTENA (aripiprazole)
2015 FDA approves REXULTI (brexpiprazole)
2017 FDA approves ABILIFY MYCITE (aripiprazole tablets with sensor) Not commercially available
2018 FDA approves JYNARQUE (tolvaptan)
2023 FDA approves ABILIFY ASIMTUFII (aripiprazole) for extended release injectable suspension
2025 FDA approves VOYXACT (sibeprenlimab-szsi)
2026 FDA approved SIMTRIYO (centanafadine) Under U.S. Drug Enforcement Administration (DEA) scheduling review
+ Loaded when opened
✅
2026-09-21 18:07 (Model: gpt-oss-20b(16) )
↑